AN EVIDENCE-BASED CKD RESEARCH SOURCE
welcome
The purpose of this space is to inform the community — both health professionals and patients and their caregivers — about current and emerging approaches being investigated for the prevention and management of Chronic Kidney Disease (CKD), including therapies recommended by international guidelines and research involving intermediary metabolites of the Krebs cycle.
3
Content developed with input from physicians in Nephrology, Internal Medicine and Endocrinology.
+50
More than 50 peer-reviewed articles, clinical trials and clinical-practice guidelines reviewed.
thank you
Thank you for your interest in our blog. If you have any questions or comments, please fill out the contact form and we will get in touch with you shortly.
DISCLAIMER: This website provides educational information about Chronic Kidney Disease and published medical research. It is not intended to diagnose disease, recommend treatment, replace medical consultation, or instruct patients to start, stop or modify medications or kidney replacement therapy. Treatment decisions should be made by a qualified healthcare professional based on the individual patient's clinical condition.
Why is CKD so relevant?
Chronic Kidney Disease (CKD) is a global health crisis (Levey AS, Atkins R, et al.) because 1 in 10 adults has some degree of CKD (stages I to V), and it ranks #7 among the top 10 causes of death among non-communicable diseases worldwide (WorldKidneyDay.org).
CKD is considered a catastrophic public health situation for five main reasons:
(Treviño BA, 2004 / Paniagua R, 2007)
Growing Number of Cases
Approximately 700 million people suffer from CKD worldwide (Nature.com).
In 2004, globally, the prevalence of patients on renal replacement therapy was about 1.8 million patients, that is, 215 patients per million inhabitants (López Cervantes, 2010).
High Costs
In England, according to a study, CKD costs more than the combined treatment of breast, lung, colon, and skin cancers (WorldKidneyDay.Org).
According to the Renal Data System 2012 of the United States, the annual cost of treating a patient on hemodialysis is about $87,000 USD, or about $7,250 USD per month.
Limited Infrastructure and Staff
Dialysis sessions are shortened to accommodate more patients due to shortages of nephrologists, technicians, nurses, surgeons, and support staff (Prasad N, Jha V, 2015).
In Mexico, more than 129,000 patients require life-sustaining renal replacement therapy, but only about half receive some form of treatment (López Cervantes, 2010).
Late Detection
CKD is a silent disease — people show no signs or symptoms until the final stages (WorldKidneyDay.Org).
In as little as 2 to 3 years, kidney function can decline from 30% down to 15%.
High morbidity and mortality rates on dialysis
In Mexico, survival was about 30.6 months on peritoneal dialysis and 32 months on hemodialysis (Méndez-Durán, et al. 2010).
Reports from the Mexican Social Security Institute (IMSS) list CKD among the top 10 causes of hospital deaths.